Pancreatic ductal adenocarcinoma (PDAC) is an intractable clinical problem, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. Currently, the standard diagnostic course includes CT or MRI scans which do not have optimal sensitivity and specificity for accurately diagnosing and determining resectability status. The long-term objectives of this project are to develop an imaging agent that can sensitively and accurately detect pancreatic cancer. To that end, we are developing a targeted imaging agent to the newly identified pancreatic cancer cell surface biomarker plectin-1. Plectin-1 is specifically expressed in pancreatic cancer and not in benign inflamed conditions. It is upregulated during carcinogenesis and expressed at high levels in the advanced premetastatic PanIN III lesions. Moreover, a SPECT/CT plectin-1 targeted imaging agent has been developed and validated in numerous stringent mouse models. Experiments will be performed to optimize the imaging agent's molecular configuration and imaging modality. Outcomes will lead to a lead imaging product that will be advanced to phase II for commercial product development and clinical study.
Public Health Relevance: The overall goal of this project is to develop new imaging approaches for the detection of pancreatic cancer, determine cancer resectability status and monitor response to chemotherapy. Alternative uses include early diagnostic screening in individuals with high-risk for the development of pancreatic cancer. We will do this by chemically synthesizing imaging agents and testing them in mouse models of pancreatic cancer. We will also test whether PET or SPECT imaging has the best characteristics for imaging pancreatic cancer.
Thesaurus Terms: 500-Kda Hd1 Protein;Abdomen;Abdominal;Abscission;Address;Affinity;Animal Model;Animal Models And Related Studies;Animals;Benign;Binding;Binding (Molecular Function);Blood Serum;Cat Scan;Ct X Ray;Ct Scan;Cancer Induction;Cancers;Cell Surface;Characteristics;Chemistry;Clinical;Clinical Research;Clinical Study;Comorbidity;Computed Tomography;Computerized Axial Tomography (Computerized Tomography);Detection;Development;Diagnosis;Diagnostic;Diagnostic Findings;Disease;Disorder;Drug Kinetics;Emi Scan;Early Diagnosis;Echography;Echotomography;Emotional Stress;Excision;Exhibits;Extirpation;Fna;Family;Fine Needle Aspirate;Fine Needle Aspiration Biopsy;Fine-Needle Aspiration;Goals;Hplc;Health;High Performance Liquid Chromatography;High Pressure Liquid Chromatography;High Speed Liquid Chromatography;Human;Image;In Vitro;Individual;Kidney;Kidney Urinary System;Label;Lead;Lesion;Life;Mr Imaging;Mr Tomography;Mri;Mri Scans;Magnetic Resonance Imaging;Magnetic Resonance Imaging Scan;Malignant Neoplasms;Malignant Pancreatic Neoplasm;Malignant Tumor;Malignant Neoplasm Of Pancreas;Man (Taxonomy);Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance;Medical Imaging, Single Photon Emission Computed Tomography;Medical Ultrasound;Metastasis;Metastasize;Metastatic Neoplasm;Metastatic Tumor;Methods;Mice;Mice Mammals;Modern Man;Molecular Configuration;Molecular Conformation;Molecular Interaction;Molecular Stereochemistry;Monitor;Murine;Mus;Nmr Imaging;Nmr Tomography;Neoplasm Metastasis;Newly Diagnosed;Nuclear Magnetic Resonance Imaging;Outcome;Pet;Pet Scan;Pet Imaging;Petscan;Pett;Panin;Pancreas;Pancreas Cancer;Pancreas Ductal Adenocarcinoma;Pancreas Neoplasms;Pancreas Tumor;Pancreatic;Pancreatic Cancer;Pancreatic Duct Dysplasia;Pancreatic Ductal Adenocarcinoma;Pancreatic Ductal Dysplasia;Pancreatic Intraepithelial Neoplasia;Pancreatic Tumor;Patients;Pb Element;Peptides;Pharmacokinetics;Phase;Positron Emission Tomography Medical Imaging;Positron Emission Tomography Scan;Positron-Emission Tomography;Procedures;Process;Prognosis;Publishing;Rad.-Pet;Removal;Resectable;Resistance;Risk Factors;Spect;Spect Imaging;Sampling;Screening Procedure;Secondary Neoplasm;Secondary Tumor;Sensitivity And Specificity;Serum;Signs And Symptoms;Single Photon Emission Computed Tomography (Spect);Single-Photon Emission-Computed Radionuclide Tomography;Staging;Surface;Surgeon;Surgical Removal;Survival Rate;Testing;Therapeutic Human Experimentation;Therapeutic Research;Time;Tomodensitometry;Tomography, Emission-Computed, Single-Photon;Tumor Cell Migration;Ultrasonic Imaging;Ultrasonogram;Ultrasonography;Ultrasound Diagnosis;Ultrasound Medical Imaging;Ultrasound Test;Work;X-Ray Cat Scan;X-Ray Computed Tomography;X-Ray Computerized Tomography;Xray Computed Tomography;Zeugmatography;Biomarker;Cancer Metastasis;Carcinogenesis;Catscan;Chelation;Chemotherapy;Chronic Pancreatitis;Clinical Relevance;Clinically Relevant;Co-Morbidity;Computed Axial Tomography;Computerized Axial Tomography;Computerized Tomography;Conformation;Conformational State;Cost;Developmental;Diagnostic Ultrasound;Dimer;Disease Control;Disease/Disorder;Disorder Control;Dosimetry;Early Detection;Experiment;Experimental Research;Experimental Study;Heavy Metal Pb;Heavy Metal Lead;Hemidesmosomal Protein Hd1;High Risk;Imaging;Imaging Method;Imaging Modality;Improved;In Vivo;Malignancy;Manufacturing Process;Model Organism;Molecular Imaging;Monomer;Mouse Model;Neoplasm/Cancer;Novel;Outcome Forecast;Pancreas Duct Dysplasia;Pancreas Ductal Dysplasia;Pancreatic Cancer Cells;Pancreatic Neoplasia;Pancreatic Neoplasm;Plectin;Product Development;Recurrent Pancreatitis;Renal;Research Study;Resection;Resistant;Response;Scale Up;Screening;Screenings;Sonogram;Sonography;Sound Measurement;Tool;Tumor;Tumor Cell Metastasis;Ultrasound;Ultrasound Imaging;Ultrasound Scanning
